{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:26:46Z","timestamp":1793467606913,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T00:00:00Z","timestamp":1441843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"MPN Voice (MOSAICC case-control study); MPN Voice (to G.J., PhD candidate at Queen's University Belfast)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>The myeloproliferative neoplasms (MPN) including polycythaemia vera (PV), essential thrombocythaemia and primary myelofibrosis (PMF) are rare diseases contributing to significant morbidity. Symptom management is a prime treatment objective but current symptom assessment tools have not been validated compared to the general population. The MPN\u2010symptom assessment form (MPN\u2010SAF), a reliable and validated clinical tool to assess MPN symptom burden, was administered to MPN patients (<jats:italic>n<\/jats:italic>\u2009=\u2009106) and, for the first time, population controls (<jats:italic>n<\/jats:italic>\u2009=\u2009124) as part of a UK case\u2013control study. Mean symptom scores were compared between patients and controls adjusting for potential confounders. Mean patient scores were compared to data collected by the Mayo Clinic, USA on 1,446 international MPN patients to determine patient group representativeness. MPN patients had significantly higher mean scores than controls for 25 of the 26 symptoms measured (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05); fatigue was the most common symptom (92.4% and 78.1%, respectively). Female MPN patients suffered worse symptom burden than male patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and substantially worse burden than female controls (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Compared to the Mayo clinic patients, MPN\u2010UK patients reported similar symptom burden but lower satiety (<jats:italic>P<\/jats:italic>\u2009=\u20090.046). Patients with PMF reported the worst symptom burden (88.3%); significantly higher than PV patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). For the first time we report quality of life was worse in MPN\u2010UK patients compared with controls (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Am. J. Hematol. 90:864\u2013870, 2015. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24098","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T07:39:30Z","timestamp":1435217970000},"page":"864-870","source":"Crossref","is-referenced-by-count":47,"title":["Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls"],"prefix":"10.1002","volume":"90","author":[{"given":"Lesley A.","family":"Anderson","sequence":"first","affiliation":[{"name":"Centre for Public Health Queen's University Belfast Belfast Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"James","sequence":"additional","affiliation":[{"name":"Centre for Public Health Queen's University Belfast Belfast Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Duncombe","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals Southampton NHS Foundation Trust Hampshire United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mayo Clinic Cancer Centre Scottsdale Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Scherber","sequence":"additional","affiliation":[{"name":"Mayo Clinic Cancer Centre Scottsdale Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[{"name":"Mayo Clinic Cancer Centre Scottsdale Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"de Vocht","sequence":"additional","affiliation":[{"name":"School of Social and Community Medicine University of Bristol Bristol United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Clarke","sequence":"additional","affiliation":[{"name":"Centre for Public Health Queen's University Belfast Belfast Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"McMullin","sequence":"additional","affiliation":[{"name":"Centre for Cancer Research and Cell Biology Queen's University Belfast Belfast Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23690"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","unstructured":"MesaRA NiblackJ WadleighM et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internet\u2010based survey of 1179 MPD patients. Cancer. (Mesa Tefferi) Department of Hematology Mayo Clinic Rochester MN United States (Niblack) Chronic Myeloproliferative Disorders Education Foundation Scottsdale AZ United States (Wadleigh) Department of Oncology Dana Farber Cancer Institute Boston : John Wiley and Sons Inc.;2007;109(1):68\u201376.","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","unstructured":"ScherberR DueckAC JohanssonP et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN\u2010SAF): International prospective validation and reliability trial in 402 patients. Blood. Rosalind Franklin School of Medicine Chicago IL USA;2011;118:401\u2013408.","DOI":"10.1182\/blood-2011-01-328955"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","unstructured":"NielsenC BirgensHS NordestgaardBG et al. The JAK2 V617F somatic mutation mortality and cancer risk in the general population. Haematologica. (Nielsen Nordestgaard Bojesen) Department of Clinical Biochemistry Herlev Hospital Copenhagen University Hospital Denmark (Birgens Kjaer) Department of Hematology Herlev Hospital Copenhagen University Hospital Denmark (Nordestgaard Bojesen) The: Ferrata Storti Foundation (Via G. Belli 4 Pavia 27100 Italy);2011;96:450\u2013453.","DOI":"10.3324\/haematol.2010.033191"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","unstructured":"BarbuiT.Myeloproliferative neoplasms Ph\u2010negative. Eur J Cancer Suppl Educ Cancer Conv Lugano Eur Sch Oncol ECCLU 2010 Lugano SwitzerlandConference Start 20100417 Conf End 20100418Conference Publ. (Barbui) Hematology and Research Foundation Ospedali Riuniti Bergamo Italy: Elsevier Ltd;2010;8(4):6\u20137.","DOI":"10.1016\/S1359-6349(10)70681-9"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","unstructured":"PieriL GuglielmelliP VannucchiAM.Chronic myeloproliferative neoplasms: A collaborative approach. Mediterr J Hematol Infect Dis. Unita Funzionale di Ematologia Dipartimento di Area Critica Universita degli Studi Istituto Toscano Tumori Firenze.;2010Jun 21;2(2):e2010017.","DOI":"10.4084\/mjhid.2010.017"},{"key":"e_1_2_7_10_1","first-page":"439","volume-title":"World Health Organisation Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.136"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544411"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577635"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.766732"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.619608"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.05.030"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.064014"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","unstructured":"HultcrantzM KristinssonSYY AndersonTM\u2010LM et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population\u2010based study. J Clin Oncol2012;30:2995\u20133001.","DOI":"10.1200\/JCO.2012.42.1925"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712461047"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4489"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1502524"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24098","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:22:08Z","timestamp":1748467328000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1002\/ajh.24098"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24098","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,10]]}}}